Pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR)Regulations, 2015; the Board of Directors, at its meeting held today i.e. on February 12, 2026, through video conferencing deemed to be held at the registered office of the company, considered and approved the following: a. The Un-Audited Financial Results for the quarter ended December 31, 2025, prepared on a Standalone & Consolidated basis, along with Limited Review Report pursuant to Regulation 33 of the SEBI(LODR) Regulations, 2015. Further, please be informed that the necessary disclosure under Clause 11 of Para-B of Part-A of Schedule III and Regulation 30 of the SEBI LODR Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, with regard to Corporate guarantee given by the Company on behalf of Innopharm Healthcare Private Limited, subsidiary of the Company are annexed with this outcome as Annexure A.